Login
$BYSI
$0.58 -$0.02 (3.73%) Live

$BYSI 8-K SEC Filings

Filed On Filing
13 Nov 2026 8-K: Results of Operations and Financial Condition

FDA Fast Track Designation for Plinabulin plus docetaxel marks key regulatory milestone in DUBLIN-4 study population of Post-ICI Non-Squamous NSCLC with no actionable genomic alteration (AGA)

13 Oct 2026 8-K: Submission of Matters to a Vote of Security Holders

BeyondSpring Inc. (the “Company”) held its 2026 annual meeting of shareholders on October 13, 2026. A total of 20,905,921 of the Company’s ordinary shares were present or represented by proxy at the meeting, representing approximately 50...

06 Oct 2026 8-K: Completion of Acquisition or Disposition of Assets

On September 28, 2026, BeyondSpring Inc. (“BYSI” or the “Company”) entered into a Share Purchase and Collaboration Agreement (the “Agreement”) with Dalian Wanchunbulin Pharmaceuticals Ltd. (“Bulin”), a majority-owned indirect subsidiary ...

02 Oct 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On September 29, 2026, BeyondSpring Inc. (the “Company”) received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the Company’s market value ...

29 Sep 2026 8-K: Entry into a Material Definitive Agreement; Other Events

THIS SHARE PURCHASE AND COLLABORATION AGREEMENT (this “Agreement”), dated as of September 28, 2026, is made by and among BeyondSpring Inc., an exempted company incorporated and existing with limited liability under the laws of The Cayman...

18 Sep 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On September 17, 2026, BeyondSpring Inc. (the “Company”) received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s ordinary ...

14 Aug 2026 8-K: Results of Operations and Financial Condition

ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy

04 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

13 May 2026 8-K: Results of Operations and Financial Condition

AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability

25 Mar 2026 8-K: Results of Operations and Financial Condition

FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today...

15 Dec 2025 8-K: Other Events

As previously disclosed, on January 24, 2025, BeyondSpring Inc. (the “Company”) entered into a Preferred Share Purchase Agreement (each, “Purchase Agreement” and collectively, the “Purchase Agreements”) with each of Winning View Investme...

21 Nov 2025 8-K: Entry into a Material Definitive Agreement

THIS SECURITIES PURCHASE AGREEMENT (as may be amended, modified, or supplemented from time to time, this “Agreement”) is made and entered into as of November 17, 2025, by and between BeyondSpring Inc., an exempt company with limited liab...

12 Nov 2025 8-K: Results of Operations and Financial Condition

FLORHAM PARK, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today reported Q3 2025 financial results...

23 Sep 2025 8-K: Entry into a Material Definitive Agreement; Other Events

KING OF PRUSSIA, Pa., Sept. 23, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable disease drivers, today announced ...

16 Sep 2025 8-K: Submission of Matters to a Vote of Security Holders

BeyondSpring Inc. (the “Company”) held its 2025 annual meeting of shareholders on September 15, 2025. A total of 21,852,265 of the Company’s ordinary shares were present or represented by proxy at the meeting, representing approximately ...

13 Aug 2025 8-K: Results of Operations and Financial Condition

BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment

03 Jul 2025 8-K: Other Events

BeyondSpring Inc. (the “Company”) has scheduled its 2025 annual meeting of shareholders (the “2025 Annual Meeting”) for September 15, 2025. The record date for the 2025 Annual Meeting is close of business on July 25, 2025. The Company wi...

12 May 2025 8-K: Results of Operations and Financial Condition

FLORHAM PARK, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical‑stage global biopharmaceutical company focused on developing cancer therapeutics, today announced its unaudited financial results for the q...

11 Apr 2025 8-K: Changes in Registrant's Certifying Accountant

We have read the statements made by BeyondSpring Inc. under Item 4.01 of its Form 8-K dated April 11, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other state...

27 Mar 2025 8-K: Results of Operations and Financial Condition

FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced its fina...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support